AlzChem Group AG: AlzChem to supply components for corona tests
DGAP-Media / 06.05.2020 / 09:44
AlzChem to supply components for corona tests
As a supplier of raw materials for the pharmaceutical industry, AlzChem is now also helping to produce "corona tests": intermediate products from AlzChem are used in both tests that detect SARS-CoV-2 and the tests used to detect antibodies.
For many years AlzChem has been reliably supplying various pharmaceutical companies with the two intermediate products guanidine hydrochloride and guanidine thiocyanate. Both are now also used to manufacture the corona tests that are currently in great demand worldwide. In order to avoid raw material bottlenecks, AlzChem has greatly increased its production capacities for guanidine hydrochloride and guanidine thiocyanate by making a significant investment in short-term financial resources and manpower. "Business is only one aspect of this - it is at least as important for us to do our part in combating the pandemic in this global crisis. We want to do everything we can to improve the health situation of as many people as possible," emphasizes Dr. Georg Weichselbaumer, member of the Executive Board and CSO of AlzChem.
Particularly when used in combination and widely deployed, the two types of tests - the detection of viruses and the detection of antibodies - can provide a relatively accurate picture of how the infection is progressing. For those responsible to make well-founded decisions, it is particularly important to not only know how many people have been infected with SARS-CoV-2 since the tests began. The number of patients who have recovered from it is also of immense importance, as this is the only way to determine the number of people currently infected. Whether someone was infected can only be determined by detecting antibodies. A large number of pharmaceutical companies are working to make such tests available reliably and in sufficient quantities.
The AlzChem Group is a vertically integrated manufacturer of chemical products based on the so-called NCN chain. These are products with a typical nitrogen-carbon-nitrogen bond that are used in a wide range of industries, including the pharmaceutical industry, which is supplied by AlzChem with intermediate products not only for corona tests, but also for the production of vital drugs for the treatment of diabetes II, AIDS and heart disease, among other conditions.
End of Media Release
Issuer: AlzChem Group AG
Key word(s): Research/Technology
06.05.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
AlzChem Group AG |
|
Dr.-Albert-Frank-Str. 32 |
|
83308 Trostberg |
|
Germany |
Phone: |
+498621862888 |
Fax: |
+49862186502888 |
E-mail: |
[email protected] |
Internet: |
www.alzchem.com |
ISIN: |
DE000A2YNT30 |
WKN: |
A2YNT3 |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart |
EQS News ID: |
1037045 |
1037045 06.05.2020
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
344,00 |
375,22 |
376,07 |
379,26 |
422,29 |
542,22 |
540,65 |
EBITDA1,2 |
43,30 |
49,38 |
50,08 |
53,81 |
62,05 |
61,44 |
81,37 |
EBITDA-Marge3 |
12,59 |
13,16 |
13,32 |
14,19 |
14,69 |
11,33 |
|
EBIT1,4 |
27,20 |
34,19 |
30,59 |
30,71 |
37,57 |
35,90 |
55,47 |
EBIT-Marge5 |
7,91 |
9,11 |
8,13 |
8,10 |
8,90 |
6,62 |
10,26 |
Jahresüberschuss1 |
16,50 |
22,78 |
18,15 |
19,87 |
27,76 |
30,22 |
34,79 |
Netto-Marge6 |
4,80 |
6,07 |
4,83 |
5,24 |
6,57 |
5,57 |
6,44 |
Cashflow1,7 |
33,00 |
34,66 |
43,63 |
48,71 |
43,02 |
-4,24 |
72,67 |
Ergebnis je Aktie8 |
1,90 |
2,30 |
1,77 |
1,94 |
2,72 |
2,96 |
3,40 |
Dividende8 |
1,10 |
0,90 |
0,75 |
0,77 |
1,00 |
1,05 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: RSM Ebner Stolz
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
AlzChem Group |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2YNT3 |
44,900 |
Kaufen |
456,92 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
13,61 |
13,75 |
1,04 |
18,87 |
KBV |
KCV |
KUV |
EV/EBITDA |
3,06 |
6,29 |
0,85 |
7,41 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,05 |
1,20 |
2,67 |
07.05.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
30.04.2024 |
01.08.2024 |
07.11.2024 |
01.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
39,20% |
78,72% |
72,69% |
136,32% |
|
|